Archives: Speakers

Dr. Michael Schlattau joined Zurich-based ECOFIN Software and Technology AG – the
company that develops Finfox – in 2019 and has been Head of Business Consulting since
2021. Prior to that he worked as a research assistant at the Chair of International Management
at the University of the Bundeswehr Munich and as a senior consultant at EY in Munich.
Michael holds a degree in Business Administration from the University of Augsburg (Dipl.-
Kfm.) and earned his doctorate at the University of the Bundeswehr Munich. He was a visiting
scholar at Columbia University in New York and at the Higher School of Economics in
Moscow.

Henk Streefkerk is a physician scientist (MD PhD) with clinical experience in Ear- / Nose- / Throat surgery and a PhD in Neurovascular surgery. Working experience is both in big pharma (>10 years) and bio-tech (>5 years). Henk started his pharma career as a clinical pharmacologist at Organon and Actelion. He then be-came a Translational Medicine Expert at Novartis. After moving into senior safety role, he first led the safety-related aspects of the global marketing authorization application of a heart failure drug (Entresto), followed by the same for a breast cancer drug (Kisqali). At PIQUR, as Chief Medical Officer, he led the global Clinical Development Team to manage 8 global clinical studies in various stages using a Pi3K/mTor inhibitor (bimiralisib).  In view of existing quality and budget constraints, Henk has re-structured the clinical and safety departments of various biotech companies, successfully passing health authority inspections (SwissMedic / ANSM) after setting up the clinical and safety modules of the quality system. He is a co-founder of a MedTech company (Rivia.ch) which develops and commercializes software to support keeping medical oversight of clinical trials. He also setup the quality management system and information security management system according to ISO 9001 and ISO 27001/GDPR. Henk founded his own consultancy company (Streefkerk Life Sciences Consultancy), providing CMO-, Medical Director-, and Drug Safety Officer services to small biotech companies in Europe and in the USA, and is currently working as CEO of Amarna Therapeutics BV, a preclinical gene therapy company in the Netherlands.

Juliette joined Syneos Health in 2015 and is an executive leader who has 30+ years Industry Experience of which 15 years Oncology and 7 years Early Phase Oncology Focus She is also spent 11 years in Early Phase Healthy Volunteers

Juliette has spent the last 7 years providing Executive Leadership executive oversight for Global Project Delivery as well as Strategic Proposal Development and Therapeutic Adviser.

A major part of Juliette’s role is to foster Customer Relations and Alliances, consulting closely with biotechnology and pharmaceutical companies on clinical development plan design and protocol development.

Juliette holds a first degree in Psychology, a post graduate diploma in Organizational Psychology, is Six- Sigma green belt trained, a Tavistock trained Executive Coach and PMP certified

Juliette is currently heading up the Oncology Therapeutic Strategy and Innovation (TSI) leading a team of therapeutic experts in support of achieving key business objectives of the Oncology Business Unit. As TSI global head, she supports the Therapeutic Area Head in achieving growth targets by ensuring effective, customer-centric solutions are presented to customers in the Request For Proposal process.

Oren Cohen, MD, is President of Clinical Pharmacology and Chief Medical Officer, partnering with biopharmaceutical companies to optimize early clinical development through excellence in study design and execution. He has served in this position since Fortrea’s launch as an independent company in July 2023 following its spinoff from Labcorp.

Following a decade of translational research at the U.S. National Institute of Allergy and Infectious Diseases under the mentorship of Anthony Fauci, MD, Oren has more than 20 years of experience in various medical and scientific executive leadership roles in the pharmaceutical industry. Most recently, Oren served as Chief Medical Officer and head of Clinical Pharmacology Services at Labcorp Drug Development since 2017. Prior to Labcorp, he was Chief Medical Officer at Viamet Pharmaceuticals, where he worked closely with clinical investigators and key opinion leaders to formulate and execute clinical development programs across a portfolio, developing and executing strategy and protocol designs. Previously, he held several senior medical and operational leadership positions at Quintiles, now part of IQVIA.

Oren received his MD from Duke University and served his internship and residency at The New York Hospital, Cornell Medical Center in New York City. He completed his infectious diseases fellowship at the National Institute of Allergy and Infectious Diseases (NIAID) and stayed on to become an investigator in the Laboratory of Immunoregulation. Oren is also Consulting Professor of Medicine at Duke University Medical Center, a member of the Board of Visitors for Duke University School of Medicine and a Fellow of the Infectious Diseases Society of America. His research has been published in journals including The New England Journal of Medicine, Science, Proceedings of the National Academy of Sciences, Nature Medicine and the Journal of Clinical Investigation.

Jordi is a hands-on senior executive, entrepreneurial-minded, with solid experience in Computer Software, Advanced Analytics and AI, Digital Transformation, Management and Strategy Consulting, having worked in small to mid-size companies and VC-baked startups in the B2B space with strong focus in Life Sciences & Healthcare industries. I love business growth stage dynamics.